drugset / Trial / NCT01552057

A Study of Duloxetine in Fibromyalgia

NCT01552057

Phase 3 Completed 393 enrolled Eli Lilly and Company Shionogi · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to assess the effectiveness and safety of duloxetine in participants with fibromyalgia.

Timeline

Start
2012-03
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 60 mg Oral

Indications